Implication of VDR rs7975232 and FCGR2A rs1801274 gene polymorphisms in the risk and the prognosis of
autoimmune thyroid diseases in the Tunisian population
, , oraz | 26 sie 2020
O artykule
Article Category: Original Article
Data publikacji: 26 sie 2020
Zakres stron: 69 - 76
DOI: https://doi.org/10.2478/bjmg-2020-0011
Słowa kluczowe
© 2020 Mestiri S, Zaaber I, Nasr I, Marmouch H, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Distribution of VDR rs7975232 polymorphism genotypes and alleles in healthy control (n = 162), in autoimmune thyroid disease patients AITD patients (n = 162), Hashimoto’s thyroiditis patients (n = 106) and Graves’ disease patients (n = 56).
| Controls | AITD Patients | HT Patients | GD Patients | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genotypes/ Alleles | p(𝜒2) | OR (95% CI) | p(𝜒2) | OR (95% CI) | OR (95% CI) | |||||
| CC | 58(35.8) | 49(30.2) | reference | 30 (28.3) | reference | 19(33.9) | reference | |||
| CA | 68(42.0) | 69(42.6) | 0.56(0.33) | 1.20(0.72-1.99) | 49 (46.2) | 0.32(0.97) | 1.39(0.78-2.47) | 20(35.7) | 0.91 (0.01) | 0.89(0.43-1.84) |
| AA | 36(22.2) | 44(27.2) | 0.27(1.20) | 1.44(0.80-2.58) | 27(25.5) | 0.35(0.85) | 1.45 (0.74-2.82) | 17(30.4) | 0.46(0.52) | 1.44(0.66-3.12) |
| CA+AA Dominant model. | 104(64.2) | 113 (69.8) | 0.34(0.89) | 1.28(0.80-2.04) | 76 (71.7) | 0.25(1.31) | 1.41 (0.83-2.40) | 37(66.1) | 0.92(0.008) | 1.08(0.57-2.05) |
| C | 184(56.8) | 167(51.5) | reference | 109 (51.4) | reference | 58(51.8) | reference | |||
| A | 140(43.2) | 157(48.5) | 0.20(1.59) | 1.23 (0.90-1.68) | 103 (48.6) | 0.25(1.28) | 1.24(0.87-1.75) | 54(48.2) | 0.41 (0.65) | 1.22(0.79-1.88) |
Hormone levels among the VDR and the FCGR2A genotypes in Hashimoto’s thyroiditis and Graves’ disease patients.
| HT Patients | GD Patients | |||||||
|---|---|---|---|---|---|---|---|---|
| TSH The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L. | T4 The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L. | TSH The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L. | T4 The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L. | |||||
| CC | 56.1±105.8 | 9.5±7.6 | 0.10±0.40 | 50.4±52.6 | ||||
| CA | 47.0±94.5 | NS | 8.3±4.3 | NS | 0.60±1.80 | NS | 38.4±25.2 | NS |
| AA | 117.2±176.3 | NS | 24.5+90.2 | 0.044 | 0.10±0.50 | NS | 43.3±59.2 | NS |
| RR | 110.3±182.9 | 6.4+4.6 | 0.01±0.02 | 63.7±57.2 | ||||
| RH | 68.2+118.9 | NS | 19.1+65.7 | NS | 0.40±1.50 | NS | 41.3±22.1 | NS |
| HH | 55.7+86.8 | NS | 6.9±4.8 | NS | 0.10±0.50 | NS | 31.3±23.0 | 0.015 |
Distribution of VDR rs7975232 polymorphism genotypes and alleles in autoimmune thyroid disease patients according to clinical parameters.
| Gender | Age | Anti-Tg Antibodies | Anti-TPO Antibodies | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotypes/ Alleles | F | M | <40 | ≥40 | [-] | [+] | [-] | [+] | ||||
| CC CA | 46(32.0) 58(40.2) | 3 (16.7) 11 (61.1) | NS | 8(19.0) 17(40.5) | 41 (34.2) 52(43.3) | NS | 18(41.0) 17(38.6) | 12(26.7) 15 (33.3) | NS | 13 (34.2) 14(36.8) | 18(37.6) 15 (31.2) | NS |
| AA | 40(27.8) | 4(22.2) | NS | 17(40.5) | 27(22.5) | 9(20.4) | 18(40.0) | NS | 11 (29.0) | 15(31.2) | NS | |
| CA+AA Dominant model. | 98(68.0) | 15 (83.3) | NS | 34(81.0) | 79(65.8) | NS | 26(59.0) | 33 (73.3) | NS | 25 (65.8) | 30(62.5) | NS |
| C | 150(52.0) | 17(47.2) | 33 (39.3) | 134(55.8) | 53 (60.2) | 39(43.3) | 40(52.6) | 51(53.1) | ||||
| A | 138(48.0) | 19(52.8) | NS | 51 (60.7) | 106(44.2) | 35(39.8) | 51 (56.7) | 36(47.4) | 45 (46.9) | NS | ||
Distribution of VDR rs7975232 polymorphism genotypes and alleles in Graves’ disease patients according to clinical parameters.
| Gender | Age | Anti-Tg Antibodies | Anti-TPO Antibodies | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotypes/ Alleles | F | M | <40 | ≥40 | [-] | [+] | [-] | [+] | ||||
| CC | 17(37.8) | 2(18.2) | 3 (20.0) | 16(39.0) | 7(53.9) | 3 (21.4) | 6(42.8) | 5(38.5) | ||||
| CA | 13 (28.9) | 7(63.6) | NS | 3 (20.0) | 17(41.5) | NS | 4(30.7) | 5 (35.7) | NS | 4(28.6) | 5 (38.5) | NS |
| AA | 15 (33.3) | 2(18.2) | NS | 9(60.0) | 8 (19.5) | p95 Fisher’s exact test. | 2(15.4) | 6(42.9) | NS | 4(28.6) | 3 (23.0) | NS |
| CA+AA Dominant model. | 28(62.2) | 9(81.8) | NS | 12(80.0) | 25(61.0) | NS | 6(46.1) | 11 (78.6) | NS | 8(57.2) | 8(61.5) | NS |
| C | 47(52.2) | 11 (50.0) | 9(30.0) | 49 (59.8) | 18(69.2) | 11 (39.3) | 16(57.1) | 15 (57.7) | ||||
| A | 43 (47.8) | 11 (50.0) | NS | 21 (70.0) | 33 (40.2) | 8(30.8) | 17(60.7) | 12(42.9) | 11 (42.3) | NS | ||
Distribution of FCGR2A rs1801274 polymorphism genotypes and alleles in healthy controls (n = 162), autoimmune thyroid disease patients (n = 162), Hashimoto’s thyroiditis patients (n = 106) and Graves’ disease patients (n = 56).
| Controls | AITD Patients | HI Patients | GD Patients | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genotypes/ Alleles | p(𝜒2) | OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||||
| RR | 62(38.3) | 43 (26.6) | reference | 24 (22.6) | reference | 19(34.0) | reference | |||
| RH | 73 (45.0) | 78(48.1) | 0.11 (2.43) | 1.54(0.93-2.54) | 57(53.8) | 0.026 (4.95) | 2.01 (1.12-3.62) | 21 (37.5) | 0.99(0.00) | 0.93 (0.46-1.90) |
| HH | 27(16.7) | 41 (25.3) | 0.019(5.43) | 2.18 (1.17-4.07) | 25(23.6) | 0.026(4.91) | 2.39 (1.16-4.91) | 16(28.5) | 0.15 (1.98) | 1.93 (0.86-4.34) |
| RH+HH Dominant model. | 100(61.7) | 119(73.4) | 0.030(4.56) | 1.71 (1.07-2.74) | 82 (77.4) | 0.01 (6.48) | 2.11 (1.21-3.68) | 37(66.0) | 0.67(0.17) | 1.20(0.63-2.28) |
| R | 197(60.8) | 164(50.6) | reference | 105(49.5) | reference | 59(52.7) | reference | |||
| H | 127(39.2) | 160(49.4) | 0.011 (6.40) | 1.51 (1.10-2.06) | 107(50.5) | 0.012(6.17) | 1.58(1.11-2.24) | 53 (47.3) | 0.16(1.94) | 1.39(0.90-2.14) |
Distribution of FCGR2A rs1801274 polymorphism genotypes and alleles in Hashimoto’s thyroiditis patients according to clinical parameters.
| Gender | Age | Anti-Tg Antibodies | Anti-TPO Antibodies | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotypes/ Alleles | F | M | <40 | ≥40 | [-] | [+] | [-] | [+] | ||||
| RR | 24(24.3) | 0(0.0) | 6(22.3) | 18(22.8) | 6(19.3) | 6(19.3) | 5(20.8) | 6(17.1) | ||||
| RH | 54(54.5) | 3 (42.9) | NS | 16(59.2) | 41 (51.9) | NS | 15 (48.4) | 17(54.9) | NS | 12 (50.0) | 19(54.3) | NS |
| HH | 21 (21.2) | 4(57.1) | NS | 5(18.5) | 20(25.3) | NS | 10 (32.3) | 8(25.8) | NS | 7(29.2) | 10(28.6) | NS |
| RH+HH Dominant model. | 75(75.7) | 7(1.0) | NS | 21 (77.7) | 61 (77.2) | NS | 25 (80.7) | 25(80.7) | NS | 19(79.2) | 29(82.9) | NS |
| R | 102(51.5) | 3(21.4) | 28(51.8) | 77(48.7) | 27(43.5) | 29(46.8) | 22(45.8) | 31 (44.3) | ||||
| H | 96(48.5) | 11 (78.6) | p Fisher’s exact test. | 26(48.2) | 81 (51.3) | NS | 35 (56.5) | 33 (53.2) | NS | 26(54.2) | 39(55.7) | NS |